Glucose transport and microvillus membrane physical properties along the crypt-villus axis of the rabbit.

Both transport function and microvillus membrane physical properties evolve as the enterocyte matures and migrates up the crypt-villus axis. We isolated enriched fractions of villus tip, mid-villus, and crypt enterocytes from which microvillus membrane vesicles were prepared. Using this material we characterized the alterations that occur in microvillus membrane fluidity as the rabbit enterocyte matures and correlated these with kinetic studies of glucose transport. With increasing maturity the microvillus membrane becomes more rigid due to both an increase in the cholesterol/phospholipid ratio and alterations in individual phospholipid subclasses. Maximal rates of glucose transport were greatest in microvillus membrane vesicles prepared from mature cells. However, the glucose concentration producing half-maximal rates of transport (Km) was significantly lower in crypt microvillus membrane vesicles, suggesting that a distinct glucose transporter existed in crypt enterocytes. This distinction disappeared when differences between membrane lipid environments were removed. By fluidizing villus-tip microvillus membrane vesicles, in vitro, to levels seen in the crypt microvillus membrane, we observed a reduction in the Km of this transport system. These data suggest that the kinetic characteristics of the sodium-dependent glucose transporter are dependent upon its local membrane environment.

[Emergency treatment of alcoholics. Review of the admissions and readmissions to a psychiatric department with regard to the features of the group]. / Akut behandling af alkoholmisbrugere. Gennemgang af indlaeggelser og genindlaeggelser på psykiatrisk afdeling med henblik på gruppekendetegn.

A retrospective investigation revealed 107 patients (29 women and 78 men) with the diagnosis of alcoholism who were admitted to the County Hospital in Vordingborg during a period of six months. Readmissions of these patients during the subsequent two years were registered. The object of the investigation was to characterize these patients as regards the mental and social conditions, as it was our impression that these conditions were of significance in the referral for treatment in the psychiatric department. In addition, we have investigated whether it is possible to point out prognostic factors for the frequency of readmission. 78% of the patients were between 30 and 50 years. Patients in social class 8 were overrepresented. This supports the presumption that admission to a psychiatric department is not based on the abuse per se but rather on the problem complex of abuse, mental and social problems. 2/3 of the patients had previously been treated for alcohol abuse. The frequency of readmission during the subsequent two years was highest for patient aged 30-50 years. In the age group 30-39 years, changes in the social and mental circumstances had occurred and, in the age group 40-49 years, somatic complications on account of the abuse had more frequently developed. No connection could be found between the duration of the first admission in the period of investigation and the frequency of readmission during the subsequent two years. It is concluded that the group of patients aged 30-39 years appears to require social initiative whereas the group of patients aged 40-49 years has a greater need for somatic treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

The GBS scale in multi-infarct dementia and senile dementia of Alzheimer type.

The GBS profile was assessed for 39 patients with multi-infarct dementia (MID) and 34 patients with senile dementia of Alzheimer type (SDAT). The MID patients fulfilled the DSM-III criteria for multi-infarct dementia and had a score of 7 points or more on the Hachinski Ischemic Scale (HIS) and a score of 4 points or less on the Gustafson/Nilsson Alzheimer Scale (GNAS). The SDAT patients fulfilled DSM-III criteria for primary degenerative dementia and had a score of 5 points or more on the GNAS and a score of 6 points or less on the HIS. The total GBS score, the GBS subscale and relative subscale scores for intellectual functioning were significantly higher in patients with SDAT as compared with patients with MID. However, these subscale scores were considerably dispersed and nearly totally overlapping between patients with MID and SDAT, which implicates that the discriminative value is minimal. The validity between the GBS versus HIS and between the GBS versus GNAS was divergent, suggesting that the GBS scale has its own unique validity. In conclusion, the study does not support the hypothesis that the GBS profile may be of diagnostic value in clinical differentiation between multi-infarct dementia (MID) and senile dementia of Alzheimer type (SDAT).

Urinary excretion of albumin and retinol-binding protein in lithium-treated patients.

Urinary excretion of albumin and retinol-binding protein was measured by means of sensitive and specific immunochemical methods in a transverse study of 20 lithium-treated patients and 24 apparently healthy individuals. Albumin creatinine clearance ratios were significantly higher in the lithium-treated patients, which may indicate glomerular lesions. Microalbuminuria correlated highly to duration of lithium therapy. No significant difference between the retinol-binding protein creatinine clearance ratios in the two groups could be shown. This suggests that the catabolism of low-molecular-mass proteins in the proximal tubules was normal.

Isolation of two novel human RhoGEFs, ARHGEF3 and ARHGEF4, in 3p13-21 and 2q22.

RhoGEFs play an important role in various signaling cascades and are implicated in human conditions like cancer and mental retardation. A database search combined with screening of a human neuronal teratocarcinoma library identified two novel RhoGEFs, ARHGEF3 and ARHGEF4 (HGMW-approved symbols). The widely expressed ARHGEF3 transcript of 3561 nucleotides encodes a polypeptide of 526 amino acids with homology to NET1. The ARHGEF4 gene generates two transcripts of 3665 and 4000 nucleotides that translate into 720 amino acid residues. Expression of ARHGEF4 is restricted to brain and the encoded protein shows homology to collybistin. FISH analysis of genomic clones mapped ARHGEF3 to 3p13-21 and ARHGEF4 to 2q22.

A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.

Seventy-two patients fulfilling the DSM-III criteria for schizophrenia and schizophreniform psychosis were admitted to a multicentre, double-blind controlled study to evaluate the efficacy and safety of remoxipride in comparison to haloperidol. The mean daily dose of remoxipride at the end of treatment was 353 mg and of haloperidol, 11 mg. Patients were assessed each week on the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) and the symptoms checklist. No significant differences in efficacy were found between the two treatments. The median total BPRS score in the remoxipride group was 25 at start of active treatment and 17 at the last valid rating (n = 31). For the haloperidol group the corresponding figures were 24 and 15 (n = 29). According to the CGI, 40% of remoxipride patients and 50% of haloperidol patients were much or very much improved. Treatment-emergent extrapyramidal symptoms, such as akathisia and rigidity, occurred significantly more frequently, and were more severe during treatment with haloperidol than with remoxipride (p = 0.012 and 0.024, respectively). Haloperidol-treated patients reported significantly more drowsiness and increased sleep during treatment (p = 0.026 and 0.012, respectively). No statistically significant differences were seen in endocrine or autonomic symptoms. Remoxipride seemed to be as effective as haloperidol, had a lower frequency of side effects, and was used safely in the dose range 150-600 mg/day.